Company profile
Mesoblast Limited
Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases
- Industry
- Biotechnology Research
- Employees
- 122
- Headquarters
- Melbourne, VIC
- Founded
- 2004
- LinkedIn followers
- 12,698
- Office locations
- 3
Mesoblast Limited company summary
Mesoblast Limited is a company in the Biotechnology Research industry, headquartered in Melbourne, VIC, founded in 2004. On LinkedIn the company has around 122 employees and 12,698 followers. The company lists 3 office locations. Its listed specialties include Cell-based therapies, cellular medicines, Mesenchymal Lineage Adult Stem Cells, regenerative medicine, COVID-19.
What technology does Mesoblast Limited use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Mesoblast Limited
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
Specialties
Where is Mesoblast Limited located?
Mesoblast Limited lists 3 office locations.
Compare companies similar to Mesoblast Limited
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Mesoblast Limited mesoblast.com | Biotechnology Research | 122 | 2004 | Melbourne, VIC |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Mesoblast Limited
What does Mesoblast Limited do?
Mesoblast (ASX:MSB; Nasdaq:MESO) is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases with significant, unmet medical needs. The Company's Phase 3 off-the-shelf mesenchymal lineage cell product candidates are: • RYONCIL™ (remestemcel-L) for steroid-refractory acute graft versus host disease (acute GVHD) • Remestemcel-L for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection • REVASCOR® for advanced chronic heart failure, and • MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide. Mesoblast’s approach to product development is to ensure rigorous scientific investigations are performed with well-characterized cell populations in order to understand mechanisms of action for each potential indication. Extensive preclinical translational studies guide clinical trials that are structured to meet stringent safety and efficacy criteria set by international regulatory agencies. All trials are conducted under the continuing review of independent Data Safety Monitoring Boards comprised of independent medical experts and statisticians. Mesoblast has an extensive patent portfolio comprising approximately 1,000 patents and patent applications with protection extending through 2040 in all major markets. This intellectual property portfolio covers composition of matter, manufacturing, and therapeutic applications of mesenchymal lineage cells. The Company believes this patent estate provides strong global protection.
How many employees does Mesoblast Limited have?
Mesoblast Limited has around 122 employees on LinkedIn.
Where is Mesoblast Limited headquartered?
Mesoblast Limited is headquartered in Melbourne, VIC.
Where does Mesoblast Limited have offices?
Mesoblast Limited lists 3 office locations, including Melbourne, VIC, AU; New York, New York, US; Singapore, Singapore, SG.
When was Mesoblast Limited founded?
Mesoblast Limited was founded in 2004.
Build a lead list from companies like Mesoblast Limited
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.